Aarey Drugs & Pharma
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Dec 4 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS LTD - TO ISSUE 5 MILLION WARRANTS
Source text: [ID:]
Further company coverage: ADPH.NS
(([email protected];))
Dec 4 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS LTD - TO ISSUE 5 MILLION WARRANTS
Source text: [ID:]
Further company coverage: ADPH.NS
(([email protected];))
Nov 29 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER ISSUE OF SHARES
Source text: ID:nBSEbn4KYR
Further company coverage: ADPH.NS
(([email protected];;))
Nov 29 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER ISSUE OF SHARES
Source text: ID:nBSEbn4KYR
Further company coverage: ADPH.NS
(([email protected];;))
Nov 26 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS - TO CONSIDER A PROPOSAL FOR ISSUANCE OF EQUITY SHARES
Further company coverage: ADPH.NS
(([email protected];))
Nov 26 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS - TO CONSIDER A PROPOSAL FOR ISSUANCE OF EQUITY SHARES
Further company coverage: ADPH.NS
(([email protected];))
Aug 7 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS LTD - TO CONSIDER ISSUANCE OF SHARES VIA PREFERENTIAL ALLOTMENT
Source text for Eikon: ID:nBSE1SNkdV
Further company coverage: ADPH.NS
(([email protected];))
Aug 7 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
AAREY DRUGS AND PHARMACEUTICALS LTD - TO CONSIDER ISSUANCE OF SHARES VIA PREFERENTIAL ALLOTMENT
Source text for Eikon: ID:nBSE1SNkdV
Further company coverage: ADPH.NS
(([email protected];))
June 21 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER AND APPROVE EXPANSION, RAISING FUNDS FROM BANK
DECISION IS WITHHELD AND WILL BE FINALIZED IN FORTHCOMING BOARD MEETING
Source text for Eikon: ID:nNSEb16vHy
Further company coverage: ADPH.NS
(([email protected];))
June 21 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER AND APPROVE EXPANSION, RAISING FUNDS FROM BANK
DECISION IS WITHHELD AND WILL BE FINALIZED IN FORTHCOMING BOARD MEETING
Source text for Eikon: ID:nNSEb16vHy
Further company coverage: ADPH.NS
(([email protected];))
June 16 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER ISSUANCE OF SHARES BY PREFERENTIAL ALLOTMENT
Source text for Eikon: ID:nBSE934WG0
Further company coverage: ADPH.NS
(([email protected];;))
June 16 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
TO CONSIDER ISSUANCE OF SHARES BY PREFERENTIAL ALLOTMENT
Source text for Eikon: ID:nBSE934WG0
Further company coverage: ADPH.NS
(([email protected];;))
May 29 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
MARCH-QUARTER PROFIT 3.6 MILLION RUPEES VERSUS LOSS 7.6 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 1.58 BILLION RUPEES VERSUS 1.2 BILLION RUPEES
Source text for Eikon: ID:nBSE1cnvHC
Further company coverage: ADPH.NS
(([email protected];))
May 29 (Reuters) - Aarey Drugs and Pharmaceuticals Ltd ADPH.NS:
MARCH-QUARTER PROFIT 3.6 MILLION RUPEES VERSUS LOSS 7.6 MILLION RUPEES
MARCH-QUARTER REVENUE FROM OPERATIONS 1.58 BILLION RUPEES VERSUS 1.2 BILLION RUPEES
Source text for Eikon: ID:nBSE1cnvHC
Further company coverage: ADPH.NS
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Aarey Drugs & Pharma do?
Aarey Drugs & Pharmaceuticals Ltd. specializes in manufacturing drugs and intermediates like metronidazole and nitro imidazole. Their product focus areas include Allergy, Dermatology, and Infectious Diseases.
Who are the competitors of Aarey Drugs & Pharma?
Aarey Drugs & Pharma major competitors are Gennex Laboratories, Chemkart India, Syschem (India), Ambalal Sarabhai Ent, Kerala Ayurveda, Coral Laboratories, Nectar Lifesciences. Market Cap of Aarey Drugs & Pharma is ₹228 Crs. While the median market cap of its peers are ₹225 Crs.
Is Aarey Drugs & Pharma financially stable compared to its competitors?
Aarey Drugs & Pharma seems to be less financially stable compared to its competitors. Altman Z score of Aarey Drugs & Pharma is 3.5 and is ranked 5 out of its 8 competitors.
Does Aarey Drugs & Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Aarey Drugs & Pharma latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Aarey Drugs & Pharma allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Aarey Drugs & Pharma balance sheet?
Balance sheet of Aarey Drugs & Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Aarey Drugs & Pharma improving?
The profit is oscillating. The profit of Aarey Drugs & Pharma is ₹4.52 Crs for TTM, ₹4.02 Crs for Mar 2025 and ₹4.68 Crs for Mar 2024.
Is the debt of Aarey Drugs & Pharma increasing or decreasing?
Yes, The net debt of Aarey Drugs & Pharma is increasing. Latest net debt of Aarey Drugs & Pharma is ₹48.56 Crs as of Mar-26. This is greater than Mar-25 when it was ₹33.38 Crs.
Is Aarey Drugs & Pharma stock expensive?
Yes, Aarey Drugs & Pharma is expensive. Latest PE of Aarey Drugs & Pharma is 57.49, while 3 year average PE is 33.43. Also latest EV/EBITDA of Aarey Drugs & Pharma is 38.56 while 3yr average is 37.81.
Has the share price of Aarey Drugs & Pharma grown faster than its competition?
Aarey Drugs & Pharma has given better returns compared to its competitors. Aarey Drugs & Pharma has grown at ~8.01% over the last 10yrs while peers have grown at a median rate of 8.0%
Is the promoter bullish about Aarey Drugs & Pharma?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Aarey Drugs & Pharma is 37.71% and last quarter promoter holding is 39.06%
Are mutual funds buying/selling Aarey Drugs & Pharma?
There is Insufficient data to gauge this.